A search for general regulators of cancer metastasis has yielded a set of microRNAs for which expression is specifically lost as human breast cancer cells develop metastatic potential. Here we show that restoring the expression of these microRNAs in malignant cells suppresses lung and bone metastasis by human cancer cells in vivo. Of these microRNAs, miR-126 restoration reduces overall tumour growth and proliferation, whereas miR-335 inhibits metastatic cell invasion. miR-335 regulates a set of genes whose collective expression in a large cohort of human tumours is associated with risk of distal metastasis. miR-335 suppresses metastasis and migration through targeting of the progenitor cell transcription factor SOX4 and extracellular matrix component tenascin C. Expression of miR-126 and miR-335 is lost in the majority of primary breast tumours from patients who relapse, and the loss of expression of either microRNA is associated with poor distal metastasis-free survival. miR-335 and miR-126 are thus identified as metastasis suppressor microRNAs in human breast cancer.
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Although metastasis is the overwhelming cause of mortality in patients with solid tumours, our understanding of its molecular and cellular determinants is limited [1] [2] [3] . Transcriptional profiling has revealed sets of genes, or 'signatures', for which expression in primary tumours correlates with metastatic relapse or poor survival 4 . Some of these genes endow cancer cells with a more invasive phenotype, enhanced angiogenic and intravasation activity, the ability to exit from the circulation, or an ability to modify the metastasis microenvironment 5, 6 . Such gene sets are thus providing numerous candidate mediators of metastasis to be validated through functional and clinical studies. Much less insight, however, has been gained into the regulatory networks that establish such altered gene expression states 7 . MicroRNAs (miRNAs) are attractive candidates as upstream regulators of metastatic progression because miRNAs can posttranscriptionally regulate entire sets of genes 8, 9 . Recent work has revealed important roles for miRNAs and miRNA processing in tumorigenesis [10] [11] [12] . Large sets of miRNAs are underexpressed in human tumours compared to normal tissues 13 , and interfering with miRNA processing enhances experimental tumorigenesis 11 . These findings suggest that this class of regulators contains suppressors of tumour progression and possibly metastasis. Therefore, we sought to identify human miRNAs that affect breast cancer metastasis to lung and bone-the two main sites of metastatic spread in this highly prevalent form of cancer.
Identification of miRNAs that suppress metastasis
We performed array-based miRNA profiling 14 of MDA-MB-231 human breast cancer cell derivatives that are highly metastatic to bone (1833 or 2287; denoted BoM1 lines) or lung (4175, 4173, 4180 and 4142; LM2 lines), as well as the parental, unselected MDA-MB-231 cell population. Out of 453 human miRNAs assayed, 179 miRNAs were expressed above background levels in one or more of the highly metastatic cells (data not shown). Notably, hierarchical clustering based on the expression of these miRNAs correctly classified the MDA-MB-231 derivatives into three groups comprising the BoM1 lines, the LM2 lines and the parental lines, respectively.
Hierarchical clustering on the basis of the expression of the 20 miRNAs for which expression was most altered across various cell lines again correctly classified the MDA-MB-231 derivatives into these three groups (Fig. 1a) . The most salient finding was a set of eight miRNAs for which expression was decreased across all metastatic sub-lines compared with their expression in the parental line (Fig. 1a) . Through quantitative stem-loop polymerase chain reaction (qRT-PCR), we were able to validate the differential expression of seven of these miRNAs in MDA-MB-231 and representative LM2 and BoM1 sub-lines ( Supplementary Fig. 1 ).
We focused on the six miRNAs (miR-335, miR-126, miR-206, miR-122a, miR-199a*, miR-489) whose expression was most decreased in metastatic cells on the basis of the combination weight of fold change in hybridization and PCR-based detection methods. Restoring the expression of miR-335, miR-126 or miR-206 in LM2 cells through retroviral transduction 10, 15 ( Supplementary Fig. 2 ) decreased the lung colonizing activity of these cells by more than fivefold (Fig. 1b) . Restoration of miR-122a, miR-199a* or miR-489 expression decreased lung colonization at early time points but did not result in a significant decrease in lung colonization at the end point ( Supplementary Fig. 3 ). Histological assessment of lungs revealed a marked decrease in the number of metastatic foci where bioluminescence imaging revealed a significant reduction ( Fig. 1c and Supplementary Fig. 4 ). The decreased expression of these candidate miRNAs in both lung and bone metastatic cells suggested a role for these molecules in general metastatic activity of breast cancer cells. Indeed, expression of miR-335, miR-206 or miR-126 significantly decreased bone metastasis formation as assessed by bioluminescence imaging and histological analysis of hindlimbs subsequent to intracardiac injection of BoM1 cells into the arterial circulation (Fig. 1d, e) . miRNAs in cells that had metastasized relative to the inoculated population ( Supplementary Fig. 5a ). Restoration of miR-335 or miR-206 expression in LM2 cells also significantly reduced their metastatic dissemination from the primary mammary tumour site ( Supplementary Fig. 5b ). miR-126 was not included in this assay because of its inhibitory effect on mammary tumour growth (see below).
To determine whether the expression of these miRNAs is lost in other human breast cancer cells with enhanced metastatic propensity, we inoculated mice with a purified population of malignant cells (CN34) obtained from the pleural fluid of a patient with metastatic breast cancer who was treated at our institution 6 . We then isolated human tumour cells from metastatic lesions that formed in the lungs (CN34-LM1 cells) and bones (CN34-BoM1 cells) of the mice. Both the CN34-LM1 and CN34-BoM1 derivatives displayed a loss of miR-335, miR-126 and miR-206 expression relative to the parental population from which they were isolated ( Supplementary Fig. 5c ). miR-335, miR-206 and miR-126 significantly reduced the ability of CN34-LM1 and CN34-BoM1 cells to metastasize to lung ( Fig. 1f and Supplementary Fig. 5d ) and bone (Fig. 1g) , respectively. The expression of these miRNAs, therefore, is lost in multiple, independently derived, breast cancer samples and their restoration suppresses lung and bone metastasis in these distinct metastatic cell populations.
Distinct mechanisms of metastasis suppression
Cell proliferation, survival and migration are among the common functions required by tumour cells for metastatic progression in target microenvironments. Of the three miRNAs that suppressed metastasis, only miR-126 significantly suppressed overall tumour growth, as assessed by tumour volume (Fig. 2a and Supplementary  Fig. 6 ). Immunohistochemistry on these mammary tumours revealed a decrease in proliferation ( Supplementary Fig. 7a, b) , but not apoptosis ( Supplementary Fig. 7c ). Consistent with this, restoration of miR-126 reduced the proliferation rate of LM2 cells as well as CN34-BoM1 cells in vitro (Fig. 2b) . miR-126, therefore, suppresses tumorigenesis and metastasis, in part, through an inhibition of cancer cell proliferation.
In contrast to miR-126, restoring the expression of miR-335 or miR-206 did not alter the proliferation or apoptotic rates of LM2 cells 4 BM2 cells expressing individual miRNAs or the control hairpin were inoculated into the arterial circulation via intracardiac injection of athymic mice. Bone metastasis was measured by bioluminescence and quantified as the normalized hindlimb photon flux. Shown are representative mice corresponding to marked data points. n 5 6-10; horizontal line represents median signal for each cohort; P-values based on a one-tailed rank-sum test. e, Representative whole-field magnification images of haematoxylin-and eosin-stained femurs extracted from representative mice 7 weeks after intraventricular injection of indicated cancer cells. f, 2 3 10 5 primary human cancer derivative CN34-LM1 cells expressing individual miRNAs or the control vector were inoculated intravenously into immunodeficient mice. Lung colonization was measured by bioluminescence, quantified and normalized. n 5 8; error bars represent s.e.m.; P-values based on a one-sided rank-sum test. g, 2 3 10 5 primary human cancer derivative CN34-BoM1 cells expressing individual miRNAs or the control vector were inoculated into the arterial circulation via intracardiac injection of immunodeficient mice. Bone metastasis was measured by bioluminescence, quantified and normalized. n 5 9-10; error bars represent s.e.m.; P-values based on a one-tailed rank-sum test.
in vivo or in vitro but it induced an altered morphology. LM2 cells and CN34-BoM1 cells expressing miR-335 or miR-206 as a population contained a significantly lower fraction of elongated cells than did control cells ( Fig. 2c and Supplementary Fig. 8 ). Despite these morphological changes, LM2 cells expressing these miRNAs continued to express the mesenchymal marker vimentin, in vivo, suggesting that the suppression of metastasis in these cells was not due to classical mesenchymal-epithelial transition ( Supplementary Fig. 9 ). We postulated that such an alteration in shape may be associated with a decrease in cell motility, which would limit metastatic migration. Indeed, in trans-well migration assays, LM2 cells and CN34-BoM1 cells expressing miR-335 or miR-206 displayed a significant reduction in migration compared with controls (Fig. 2d) . miR-335 and miR-206 also caused a significant reduction in invasive capacity, as assessed through matrigel invasion assays ( Supplementary Fig. 10 ). These findings highlight cell-autonomous mechanisms of cell proliferation, migration and invasion through which specific miRNAs may suppress metastasis.
MicroRNA expression in clinical metastasis
To determine whether these miRNAs are associated with human metastasis, we determined by qRT-PCR the expression levels of miR-335 and miR-126 in 20 archived primary breast tumours. These tumours comprised large (.2.5 cm) and small (,2.5 cm) oestrogen receptor (ER)-positive and -negative subtypes that were surgically resected before administration of chemotherapy. This set consisted of primary tumours resected from 11 patients that ultimately relapsed to lung, bone, or brain as well as tumours resected from nine patients who did not suffer metastatic relapse (Supplementary Table 1 ). qRT-PCR ( Supplementary Fig. 11 ) revealed that patients whose primary tumours displayed low expression of miR-335, miR-126 (Fig. 3a) or miR-206 ( Supplementary Fig. 12 ) had a shorter median time to metastatic relapse. Notably, the low expression levels of miR-335 (P 5 0.0022; median survival of 1.84 yr; hazard ratio (ratio of the predicted hazard (metastasis) for a member of the control group compared to that for a member of the test group) of 8.95) or miR-126 (P 5 0.0156; median survival of 2.57 yr; hazard ratio of 5.08) were associated with very poor overall metastasis-free survival compared to the group whose tumours expressed a high level of these miRNAs. The median expression values of these miRNAs was more than eightfold lower in tumours from patients that ultimately relapsed compared to tumours from patients that did not relapse ( Supplementary Fig. 11 ). The expression levels of these miRNAs were not significantly correlated with ER status or HER-2 (also called ERBB2) amplification status (Supplementary Table 1 ). The group of patients whose primary tumours had a low level of miR-122a or miR-199a expression, two miRNAs that do not suppress metastasis, showed no difference in metastasis-free survival compared to those with high expression (Fig. 3a and Supplementary Fig. 11 ). These findings uncover a significant association between the loss of metastasis suppressor miRNA expression in primary human breast tumours and the likelihood of future distal metastatic recurrence.
miR-335 regulates a set of metastasis genes Given the strong association between the loss of miR-335 expression and clinical relapse, we wondered whether miR-335 loss could ARTICLES promote metastasis. To test this, we transfected the poorly metastatic MDA-MB-231 cells with an anti-miRNA antagomir 16 targeting either miR-335, miR-199a* or a control sequence. Indeed, inhibition of miR-335 enhanced the lung-colonizing ability of MDA-MB-231 cells compared with control cells (Fig. 3b) . To identify putative metastasis genes that miR-335 suppresses, we transcriptionally profiled LM2 cells with restored miR-335 expression and arrived at the set of 756 genes for which expression is decreased (using a permissive threshold; see Methods) compared with control LM2 cells. We separately identified genes for which expression levels were increased across both bone and lung metastatic cells. On the basis of available gene expression data sets 17, 18 we identified 116 genes for which expression was increased by at least twofold in both bone and lung metastatic MDA-MB-231 derivatives compared with the parental line (Supplementary Table 2 ). The overlap between these two lists yielded a set of six genes for which expression is high in metastatic cells and suppressed by miR-335 (Fig. 4a) . This list of miR-335-regulated metastasis genes included genes previously implicated in extracellular matrix and cytoskeleton control, such as the type 1 collagen COL1A1 (ref. 19) ; in signal transduction, such as the receptor-type tyrosine protein phosphatase PTPRN2 (ref. 20) , the c-Mer tyrosine kinase (MERTK) 21 and the phospholipase PLCB1 (ref . 22); as well as in cell migration, such as tenascin C (TNC) 23 and the SRY-box containing transcription factor SOX4 (refs 24, 25) .
Bioinformatic analysis of the 39 UTRs of these genes revealed them all to have at least six nucleotides of sequence complementarity to the miR-335 seed region (data not shown). To determine whether the altered expression of these genes in metastatic cells is, in part, mediated through their 39 UTRs, we cloned the 39 UTR of five of these genes downstream of a luciferase gene as a reporter, and assayed their expression in LM2 cells (low miR-335) and MDA-MB-231 cells (high miR-335). The expression from UTR reporters corresponding to SOX4, PTPRN2, TNC and MERTK, but not that of the control gene UBE2F lacking the miR-335 target sequence, was significantly lower in LM2 cells relative to MDA-MB-231 cells (Fig. 4b) . Furthermore, inhibition of miR-335 in MDA-MB-231 cells by means of an antagomir was sufficient to enhance the expression of SOX4, PTPRN2 and MERTK, but not the expression of a control UBE2F reporter (Fig. 4c) . These results suggest that SOX4, PTPRN2, MERTK and possibly TNC are direct targets of endogenous miR-335.
SOX transcription factors are known to regulate progenitor cell development and migration 25 . In reporter assays, mutation of the miR-335 seed sequence in the SOX4 UTR as well as miR-335 inhibition with an antagomir significantly increased reporter expression (Fig. 4d) . Restoration of miR-335 expression in LM2 cells reduced endogenous SOX4 messenger RNA expression, whereas miR-335 inhibition increased SOX4 expression in MDA-MB-231 cells (Fig. 4e) . The knockdown of SOX4 in LM2 cells with either of two unique short hairpin RNAs (shRNAs) (Supplementary Fig. 13a ) reduced the overall fraction of elongated cells, similar to the phenotype observed with miR-335 restoration in these cells (Supplementary Fig. 14a, b) . The morphological change resulting from SOX4 knockdown was also associated with a decrease in cell migration in a trans-well assay (Supplementary Fig. 14c ). Another miR-335-regulated gene, TNC, also caught our attention, as its expression occurs in the invasive front of human carcinomas 26 . Knockdown of TNC in LM2 cells using either of two RNA interference molecules also reduced migration in a trans-well assay (Supplementary Fig.  14c) . Notably, knockdown of SOX4 or TNC significantly diminished the invasive ability of LM2 cells (Fig. 5a) . Moreover, short-hairpin inhibition of SOX4 or TNC significantly abolished metastasis by LM2 cells in lung colonization assays (Fig. 5b, c) . Thus, miR-335 regulates metastasis through suppression of transcription factor SOX4 and extracellular matrix component tenascin C.
To determine whether the expression of the genes that miR-335 regulates is associated with human breast cancer metastasis, we examined primary breast tumour gene expression data sets with corresponding disease outcome annotation 18, 27 . Tumours in these cohorts for which aggregate six-gene expression scores exceeded one standard deviation from the mean were considered miR-335-signature-positive (equivalent to loss of miR-335 function). Patients whose primary breast tumours were positive for the miR-335 signature had a significantly worse metastasis-free survival both in the combined cohort of 368 patients (Fig. 5d) as well as in each cohort separately classified (Supplementary Fig. 15a ). Consistent with the results of our functional studies, the miR-335 signature performed better as a predictor of overall metastasis rather than lung-or bonespecific metastasis (Supplementary Fig. 15b ).
MicroRNAs as suppressors of metastasis
Multiple lines of evidence provided here argue for the involvement of specific miRNAs in suppressing breast cancer metastasis. miR-335, miR-206 and miR-126 are selectively downregulated across a number of highly metastatic human cell lines compared to the general tumour cell population and have demonstrated abilities to suppress metastasis of breast cancer cells to different organ sites. The expression of miR-335 and miR-126 in human mammary tumours is inversely associated with metastatic relapse of these tumours to distant organs, and the expression of miR-206 also shows a trend in the same direction. The expression of a set of genes regulated by one of these miRNAs, miR-335, is directly associated with relapse. We also establish two of these genes, SOX4 and TNC, as in vivo mediators of metastasis. The role of SOX4 in haematopoietic progenitor development 28 suggests that its transcriptional programme may be re-used not only for cancer cell invasion in cooperation with tenascin C but also for tumour initiation in the metastatic niche. miR-335 and miR-126 are expressed in normal human breast tissue 13 . Our findings on their roles in the pathogenesis of human breast cancer argue for an important function for these regulators in maintaining normal tissue integrity. Recently, miR-10b was identified as a miRNA whose overexpression in breast cancer cells promoted tumour growth and lung micrometastasis 12 . Our work expands on this by identifying miRNAs as clinically meaningful suppressors of metastasis. MicroRNAs are thus uncovered as another class of molecules, along with metastasis suppressor genes 29 , that negatively regulate tumour progression. The recent implication of miRNAs and miRNA processing in tumorigenesis 11, 13 has raised interest in identifying the specific miRNAs for which loss of expression enhances tumorigenesis, the mechanisms by which they act, and the phenotypic advantages afforded to cells that lose miRNA expression. Our findings suggest that within a tumour, the loss of specific miRNAs provides a selective advantage for cells destined for metastatic colonization. A global downregulation of miRNAs in cancer may serve metastasis by reducing the threshold for loss of specific miRNAs in a subset of cells that will ultimately metastasize. That one such miRNA (miR-335) regulates a set of putative, and a subset of validated, metastasis genes argues that the multi-gene regulatory capacity of a miRNA can function as a barrier to tumour progression in humans. The strong association of the loss of miR-335 and miR-126 expression with metastatic relapse suggests the potential for the use of these molecules in prognostic stratification of breast cancer patients in addition to conventional clinical and pathological staging markers.
METHODS SUMMARY
The MDA-MB-231 cell line and its metastatic derivatives 18, 17, 30 as well as the pleural effusion-derived CN34 cancer cells have been described previously 31 . All metastatic derivatives were obtained through in vivo selection in immunodeficient mice 17, 18 . MicroRNA microarray profiling was performed using LC Sciences technology (LC Sciences, LLC). Mature miRNA expression was assayed using Taqman MicroRNA assays as previously described 32 . MicroRNA expression was achieved through retroviral transduction of metastatic cells using miRVec technology 15 . The miRNA vectors were provided by R. Agami 10 . In brief, they consist of approximately 500-bp fragments that span a given miRNA genomic region under the control of a CMV promoter 10, 15 . All animal work was done in accordance with the MSKCC Institutional Animal Care and Use Committee. Statistical analyses were performed using the Graphpad Prism 5 software package. See Supplementary Methods for additional information regarding retroviral infections, transfections, shRNA and siRNA constructs, miRNA inhibition, analysis of miRNA and mRNA expression, miRNA expression profiling and hierarchical clustering, transcriptional profiling, tumour miRNA and gene expression analysis, survival analysis, trans-well migration and invasion assays, bioluminescence imaging, animal injections and inoculations, metastatic cell extraction, tumour and lung immunohistochemical and histological analyses, and image quantification. LM2 cells transduced with either a control short hairpin, a short hairpin targeting SOX4 or one targeting TNC were inoculated intravenously into immunodeficient mice. Lung colonization was measured by bioluminescence and quantified. n 5 7; error bars represent s.e.m.; P-values based on a one-tailed rank-sum test. c, Haematoxylin-and-eosin-stained images of representative lungs that were extracted at 4 weeks after cell inoculation. Representative images were obtained at 103 magnification. d, Kaplan-Meier curves for the combined Memorial Sloan Kettering and Erasmus Medical Center breast tumour cohorts (368 tumours) depicting metastasis-free survival of patients whose primary tumours expressed the miR-335 six-gene signature (positive) and those that did not (negative). n 5 368; P-value based on the Mantel-Cox log-rank test.
